A Study to Investigate LYL797 in Adults With Solid Tumors

a study on Breast Cancer Triple-Negative Breast Cancer Lung Cancer Non-Small Cell Lung Cancer Small Cell Carcinoma Cancer, General Solid Tumor Carcinoma Lung Tumor

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around

Description

Summary

This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC). The first part of the study will determine the safe dose for the next part of the study, and will enroll TNBC and NSCLC patients. The second part of the study will test that dose in additional TNBC and NSCLC patients.

Official Title

A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults With Relapsed and/or Refractory Solid-Tumor Malignancies

Details

This Phase 1, single-arm, open-label, multi-center, dose-escalation and -expansion study will evaluate the safety and tolerability of LYL797, ROR1-targeting CAR T cells, in adults with relapsed and/or refractory ROR1+ triple negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC). The dose-escalation phase includes TNBC and NSCLC patients, and will investigate 4 dose levels to determine the recommended Phase 2 dose (RP2D). The dose-expansion phase will enroll both TNBC and NSCLC patients at the RP2D.

Keywords

Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC, CAR T-cell therapy, CAR T, CAR T-cell, CAR-T, CAR-T cell therapy, CAR-T cell, ROR1, ROR1+, ROR1 positive, cell therapy, immunotherapy, relapsed, refractory, solid tumor, advanced, metastatic, breast cancer, lung cancer, Carcinoma, Breast Neoplasms, Lung Neoplasms, Non-Small-Cell Lung Carcinoma, Triple Negative Breast Neoplasms, Recurrence, LYL797

Eligibility

You can join if…

Open to people ages 18 years and up

  • ≥ 18 years of age at time of informed consent
  • Histologically confirmed TNBC or NSCLC that is relapsed or refractory, metastatic or locally advanced and unresectable that is ROR1+ by central laboratory immunohistochemistry (IHC)
  • Measurable disease including a target lesion and an additional lesion for biopsy
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Adequate organ and marrow function
  • Women of childbearing potential must have a negative pregnancy test at screening
  • All participants must agree to practice highly effective methods of contraception

You CAN'T join if...

  • Prior treatment with any adoptive T-cell therapy or anti-ROR1 therapy
  • Prior solid organ transplantation
  • Active, untreated brain metastasis or leptomeningeal disease; stable, treated brain involvement by disease is allowed
  • Untreated or active infection at the time of screening or leukapheresis
  • HIV-positive, HTLV-1-positive, active acute or chronic HBV or HCV, or active tuberculosis
  • Impaired cardiac function or clinically significant cardiac disease
  • Uncontrolled pleural or pericardial effusion
  • Systemic corticosteroids or other immunosuppressive medications within 14 days of leukapheresis
  • Required chronic anticoagulation, such as warfarin, low molecular weight heparin, or Factor Xa inhibitors
  • Pregnant or lactating/nursing women

Locations

  • University of California, Los Angeles accepting new patients
    Santa Monica California 90404 United States
  • Mayo Clinic accepting new patients
    Scottsdale Arizona 85259 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Lyell Immunopharma, Inc.
ID
NCT05274451
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 54 study participants
Last Updated